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Summary
Tendon lesions are among the most frequent muscu-
loskeletal pathologies. Vascular endothelial growth
factor (VEGF) is known to regulate angiogenesis.
VEGF-111, a biologically active and proteolysis-resis-
tant splice variant of this family, was recently identi-
fied. This study aimed at evaluating whether VEGF-
111 could have a therapeutic interest in tendon
pathologies. Surgical section of one Achilles tendon
of rats was performed before a local injection of ei-
ther saline or VEGF-111. After 5, 15 and 30 days, the
Achilles tendons of 10 rats of both groups were sam-
pled and submitted to a biomechanical tensile test.
The force necessary to induce tendon rupture was
greater for tendons of the VEGF-111 group (p<0.05)
while the section areas of the tendons were similar.
The mechanical stress was similar at 5 and 15 days
in the both groups but was improved for the VEGF-
111 group at day 30 (p <0.001). No difference was ob-
served in the mRNA expression of collagen III,
tenomodulin and MMP-9. In conclusion, we observed
that a local injection of VEGF-111 improves the early
phases of the healing process of rat tendons after a
surgical section. Further confirmatory experimenta-
tions are needed to consolidate our results.
KEY WORDS: biomechanical, growth factor, healing,
tendon, VEGF, VEGF-111.
Introduction
Tendinous lesions are among the most frequent
pathologies in sportsmen and physical workers1.
Tendinopathy often becomes chronic due to the cur-
rent lack of conservative treatments1. It is therefore of
interest to develop new treatments. Injection of
platelet-rich plasma (PRP) seems to be a promising
approach by releasing growth factors (GF) locally2.
Among the GF released by activated platelets, the vas-
cular endothelial growth factor-A (VEGF-A) is known to
induce positive effects on vascular function and angio-
genesis, and could be beneficial in the healing process
of tendons3. Recently, a novel VEGF-A isoform was
identified, the VEGF-111, a biologically active, dif-
fusible and proteolysis-resistant VEGF-A splice variant
generated by skipping the exons 5-73-5. Its expression
is induced in several types of cells in vitro by genotoxic
agents such as chemotherapeutic drugs and UV-B3,4.
Recombinant VEGF-111 has been shown to signifi-
cantly improve vascularization of grafted ovarian tis-
sue6, and might present potential beneficial effects on
ischemic diseases3. This prompted us to evaluate
whether VEGF-111 could have a therapeutic interest
within the framework of the tendon pathology. 
Materials and methods
All experimental procedures and protocols used in this
investigation were reviewed and approved by the Insti-
tutional Animal Care and Use Ethics Committee of the
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University of Liège (Belgium). The “Guide for the Care
and Use of Laboratory Animals,” prepared by the Insti-
tute of Laboratory Animal Resources, National Re-
search Council, and published by the National Acade-
my Press, was followed carefully. Our study meets the
etnical standards of the Journal7. We used an experi-
mental protocol very similar to our previous study on
the healing effect of PRP in tendon lesions of rats8. 
A) Sixty Sprague-Dawley male rats of 2 months (weight
± 320 g) were used. Rats were weighed and anes-
thetized i.p. with pentobarbital (60 mg/kg of body
weight). Buprenorphine (0.05 mg/kg of body weight)
and tetracycline (15 µg/kg of body weight) were sub-
cutaneously injected prior to surgery. Buprenorphin
was administred again for 3 days. The complete sur-
gical procedure was performed under aseptic condi-
tions under a dissecting microscope. Skin of the left
limb was shaved and incised laterally to the Achilles
tendon. The Achilles tendon complex was exposed
after dissection of the surrounding fascia. The plan-
taris tendon was removed to avoid mismeasure-
ments during the biomechanical testing. The
Achilles tendon was transversally cut 5mm proximal
to its calcaneal insertion and a 5-mm segment was
removed. The tendon was left unsutured with a gap
between the tendon stumps. The fascia and the skin
were sutured with resorbable yarn Vicryl 6/0
(Ethicon, Johnson & Johnson, New Brunswick, NJ).
The animals were placed in clean cages under heat-
ing lamp until awakening and there was no postop-
erative immobilization. The rats were divided into
“control” and “VEGF-111” groups that received 2
hours postoperatively a local injection (inside the de-
fect) of 50 µL of a physiological solution (control
group) or VEGF-111 (100 ng). They were checked
daily and followed for well-being and a global obser-
vation of walk and activity. 
B) Five, 15, or 30 days postsurgery, 10 rats of both
groups were weighed and euthanized with pentobar-
bital (i.p., 200 mg/Kg). The healing tendon, with the
attached calcaneal bone and a part of the triceps
suralis, was dissected from surrounding tissues. The
muscle-tendon-bone unit was fastened in the clamp-
ing device by freezing the muscular segment (triceps
surae) with liquid nitrogen and clamping it between a
“cryo-jaw” device9 and by fixing the bony segment
between the lower clamp. The cross-sectional area
of the samples was calculated from pictures made
with a set of two cameras positioned perpendicular to
each other. The traction test (106.2 kN, TesT GmbH,
Dusseldorf, Germany) was started as soon as the
expansion of the freezing zone reached the border of
the metal clamp but did not extend into the tendon
tissue. The displacement rate was set at a constant
speed of 1 mm/s until rupture. Force vs displacement
curves were recorded by a computer for subsequent
data analysis. The force at rupture or ultimate tensile
strength (UTS) was expressed in newtons (N). To
account for the difference in the cross-sectional area
of the healing tendons, the value of UTS was normal-
ized to a unit area (megapascal, MPa) and repre-
sents the mechanical stress of the tissue. 
C) Samples for biochemical analyses were taken direct-
ly after tendon rupture during the mechanical test,
snap frozen in liquid nitrogen, and stored at -80°C
until use. Isolation of total RNA from the samples
was performed using the RNeasy Total RNA Kit (Qi-
agen, Venlo, the Netherlands). The expression of
type III collagen (Col III), MMP 9 (MMP-9), and
tenomodulin (TNMD) was measured by semi-quanti-
tative reverse transcription polymerase chain reac-
tion (RT-PCR) as described previously (using an in-
ternal synthetic standard RNA)8. Expression levels of
mRNA were normalized to the level of 28S rRNA10. 
D) Results are expressed as the mean ± standard de-
viation of the mean. The results were compared by
a Friedman’s test and parametric post hoc test of
Wilcox by using the statistical software Statistical
Analysis System, version 9.1 (SAS Institute, Cary,
NC) and a level of significance at p < 0.05.
Results 
No significant difference in the body weight was ob-
served between the control and the VEGF-111 treat-
ed group at the three time points of the experiment.
Five days after surgery, UTS was low in both control
and VEGF-111 groups and significantly increased
with time in both groups (p<0.0001) (Fig. 1a), above
the basal normal values (42N)8. At day 15 and 30, the
UTS was significantly higher in the VEGF-111 group
(p<0.05).
Five days after injury, the cross-sectional area of the
tendon was similar in both groups, and continued to
similarly enlarge at day 15. At day 30, it levelled off in
the control group while it tended to decrease in the
VEGF-111 group (Fig. 1b). As a consequence of the
evolution of these parameters, the UTS per unit sur-
face (mechanical stress) of the healing tissue was
similar in both groups at day 5 and similarly increased
at day 15. However, at day 30, the VEGF-111 group
displayed significantly higher mechanical stress val-
ues (p <0.001) than the control group (Fig. 1c).
The expression of Col III mRNA was high during the
first 2 weeks and then decreased at day 30 similarly in
both groups (Tab. 1). The expression of TNMD was
low at day 5, tended to increase at day 15 and to de-
crease slowly at day 30 (Tab. 1). The expression of
mRNA coding for the MMP-9 was stable in both groups
at the three time points but tended (p=0.15) to de-
crease in the VEGF-111 group after day 15 (Tab. 1). 
Discussion
Platelets degranulation releases growth factors
stored in their granules11. VEGF is one of these
growth factors4, 12 and is known to induce positive ef-
fects on vascular function and angiogenesis4, 12.
However, this growth factor would be also implicated
in the physiopathology of tendinopathies. Indeed, a
study which applied prolonged and repetitive loading
on rabbit tendons showed that this mechanical stress
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lead to an increased production of VEGF by tendons
cells along the outer regions of the loaded tendon13.
These locations may be at-risk regions in the tendon
that will ultimately demonstrate changes typical of
tendinopathy. A study on human patellar tendons
demonstrated that VEGF expression was higher in
patients with a more recent patellar tendinopathy than
in symptomatic patient suffering of tendinopathy for a
longer time14. Authors concluded that VEGF may
contribute to the vascular hyperplasia that is a cardi-
nal feature of symptomatic tendinosis, particularly in
patients with more recent onset. This expression of
VEGF could reflect a tentative tendon healing
process that would be inhibited by the repetitive me-
chanical loading. The application of VEGF-111 in
acute tendon injury might therefore accelerate the
healing process, in absence of mechanical overload. 
VEGF-111 is a biologically active VEGF-A splicing
isoform generated by the skipping of the exons 5-7
induced by genotoxic agents such as UV-B3, 4. Due to
the lack of the proteolytic cleavage site in the exon 5,
this variant is resistant to proteolysis and has a
longer half-life than the classical VEGF-1655. In this
study, we evaluated the influence of a single postop-
erative injection of 100 ng of VEGF-111 on the repair
of ruptured Achilles tendon of rats by following me-
chanical and biochemical parameters as a function of
time during the healing process, using the same ex-
perimental protocol as previously used in our study
evaluating the effect of PRP on the tendon healing8.
Our mechanical tests showed that a VEGF-111 injec-
tion significantly improved the UTS of the healing
Achilles tendons 15 and 30 days after surgery and the
mechanical stress in the late phase (30 days) of the
repair compared to the control group (Fig. 1 a, c).
However, if we compare these results to our previous
study8, we observed that PRP-treated tendons had a
significantly higher UTS and greater cross-sectional
area increasis as compared to VEGF-111. In this
study, we did not observe any significant difference in
the cross-sectional area of tendons of both groups
(Fig. 1 b). The section area of the VEGF-111 treated
tendons levelled off after day 15, similarly to the con-
trol group but tended to decrease at day 30. Altogeth-
er, this resulted in a similar improvement of the me-
chanical stress between the VEGF-111 and PRP-
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Table 1. Expression of mRNA (in arbitrary units per unit of 28S rRNA, AU) coding for Col III, TNMD and MMP-9. Col
III: type III collagen; TNMD: tenomodulin, MMP9: matrix metalloproteinase 9.
D5 D15 D30
Col III
Control 1.302 ± 0.173 1.058 ± 0.126 0.765 ± 0196
VEGF-111 1.279 ± 0.076 1.044 ± 0.194 0.876 ± 0.291
TNMD
Control 0.336 ± 0.065 2.122 ± 0.273 1.509 ± 0.334
VEGF-111 0.378 ± 0.144 1.897 ± 0.309 1.702 ± 0.157
MMP-9
Control 1.548 ± 1.306 1.552 ± 0.549 1.418 ± 1.515
VEGF-111 1.044 ± 0.757 1.176 ± 0.573 0.800 ± 0.661
Figure 1. a) Breaking strength expressed in newton (N) recorded in control groups (n = 8 at each time point) and VEGF-111
groups (n = 10 at each time point) (mean ± SD) at increasing time after surgery (5, 15, and 30 days). *p-value < 0.05. b)
Evolution of the cross-sectional area of the tendons (square millimeter) with time (mean ± SD, n = 10 at each time point). c)
Calculated ratio between UTS and the surface area of the section of the tendon (mechanical stress in megapascal) at the 3
time points (mean ± SD, n = 10 at each time point). SD: standard deviation; UTS: ultimate tensile strength.
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treated groups although likely through different mech-
anisms. VEGF-111 alone could perhaps induce less
inflammation than PRP, due to the absence of
chemokines, inflammatory mediators and other growth
factors released by platelets, but could be enough to
improve the mechanical resistance of tendons. 
The expression of a selected number of genes rele-
vant to tendon healing process was investigated such
as Col III which is the main fibrillar collagen syn-
thetized during the healing process, TNMD which is a
marker of tenocyte differentiation and MMP-9 which
is produced by inflammatory cells. No altered level of
Col III mRNA, known to participate in the healing
process neither of TNMD, expressed by differentiat-
ing tenocytes nor MMP-9 was observed in the VEGF-
111-treated tendons (Tab. 1). However, a tendency,
although not significant, to a decreased expression of
MMP-9 mRNA was observed at day 30. MMP-9 is a
marker of tissue remodeling. This observation could
be explained by a decreased intratendinous inflam-
mation and an advanced maturation of the healing
process. This might support the improvement of the
mechanical resistance of the VEGF-111 treated ten-
dons. VEGF-165 has been reported to induce in teno-
cytes in vitro the expression of TGFβ1, a growth fac-
tor known to stimulate the production of extracellular
matrix molecules15. Further investigations are needed
to evaluate the induction of a similar mechanism by
VEGF-111. 
In opposition to the observations by Hou et al.16 who
suggested that VEGF-165 might have a negative im-
pact on tendon healing via vessel formation and de-
struction of the collagen network, and those of Sahin
et al.17 who showed that biomechanical stability of
the patellar tendons of rats was decreased 7 days af-
ter surgery concomitantly with an increase of VEGF
and MMP-3, our study suggest that VEGF-111 could
have a potential positive effect on the healing of ten-
don lesions in rats. This can be related to the differ-
ent vascular patterning induced by VEGF-165 (large
vascular lacunae) and VEG-F111 (numerous small
capillaries) as previously described in tumors3, 5. The
invasion of tendon by small capillaries could be simi-
lar to the vascularization occurring at the beginning of
the healing process in tendon, while larger vessels
would be observed in chronic tendons lesion. More-
over, this intratendinous vascularization could be
more effective to transport all the needed substrates
for healing than a more superficial vascularization.
Furthermore, a recent study, on the anterior cruciate
ligament (ACL) reconstruction, showed that VEGF
may play a positive role in the ligamentization of the
tendinous graft and healing process18. These authors
observed that using hyaluronan as a releasing carrier
of VEGF-165 can improve revascularization and bio-
mechanical properties of allografts after ACL recon-
struction, and decrease the recovery period. The in
situ concentration of VEGF might also be a factor
worth to consider.
Our study presents some limitations. It would have
been interesting to investigate the elasticity and stiff-
ness of the tendons besides their resistance to evalu-
ate another parameter of the intrinsic quality of the
healed tendons. We chose to measure the expres-
sion of collagen type III which is the main fibrillar col-
lagen synthesized by tenocytes during repair process
and not the type I collagen which is the predominant
collagen found in the healthy tendons. However, the
ratio Col I/Col III would be also a good indicator of the
healing process, taking into account the phenotype
switching during healing. 
In conclusion, this preliminary experimentation
showed that a 100ng injection of VEGF-111 stimulat-
ed tendon healing process as suggested by the in-
creased ultimate force needed to rupture tendons
during healing and the increased mechanical stress
in comparison with the control group. Other experi-
mentations with larger number of experimental ani-
mals and various concentrations of VEGF-111, possi-
bly associated with eccentric work19, are needed to
confirm these encouraging results.
Jean-François Kaux and Lauriane Janssen con-
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